Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable ...

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

is the most common form of malignant mesothelioma, that can progress rapidly. The approval marks the first indication for KEYTRUDA in MPM in the U.S. The approval was based on results from the ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the ... advanced or metastatic malignant pleural mesothelioma, a disease where prognoses are generally poor," Dr ...